The global H1N1 2009 Influenza vaccine market is estimated to be $7,028 billion by 2011, growing at a CAGR of 222.4 % from 2009 to 2011. Some of the key players in this market are GlaxoSmithKline, Novartis, CSL, MedImmune, Sanofi-Pasteur, Solvay, Sinovac Biotech and Hualun Biologicals.
Online PR News – 26-October-2009 – – Wilmington,Del.- H1N1 Influenza A (2009) is the first pandemic influenza of 21st century affecting more than more than four lac people in more than 180 countries across the globe in 2009. The flu broke in Mexico in the month of March and then affected U.S. and after that it spread across the globe. H1N1 (2009) influenza have a mutation of pig, bird and humans which has made it more dangerous and fatal compared to previous occurrence of H1N1 (1918).
Review the complete report at: http://www.marketsandmarkets.com/PressReleases/swine-Flu-vaccination-market.asp
The pandemic outbreak of the influenza opened the gates for the drugs such as Tamiflu in the initial phase for the curing of the disease but the following phase will see a shift from curing to prevention. Thus, arise the requirement for the vaccine for the treatment of H1N1. H1N1 vaccine market is the forecast for the upcoming vaccines for the prevention of the disease among the unaffected population. The vaccines market is classified for the intramuscular vaccines and intranasal vaccines. Intramuscular will cater 80-85% of market revenues and the remaining will be tapped by the intranasal vaccines. The initial lot of vaccines will be of egg based and cell based manufacturing. The market forecast is from late 2009 as the first lot of doses are expected to be rolled out in the first week of October 2009.
The first movers of the in the vaccines market are Glaxo Smith Kline (GSK), Novartis, CSL, Medimmune, Baxter, Sinovac and Sanofi Pastuer. Medimmune is the only producer of the intranasal vaccine whereas other companies are expected to come out with intramuscular vaccines. The companies have got approvals for their first lots from the governments of the various countries such as U.S., U.K., France, China, Denmark and Australia. The involvement of government bodies, increased awareness about prevention and pandemic situation of the influenza is driving the market for the vaccines.
Due to intensive ongoing research and technology introduction, the market players are compelled to understand the market dynamics, innovations, pricing, products, marketing and regulatory framework of the market.
The global H1N1 Influenza vaccine market is estimated to be of 676 million in 2009 with first lot of doses being commercialized on 30th September’ 2009. The market will see a high CAGR for the next two years i.e. the market is expected to be at $7.03 billion in 2011 with a CAGR of 222.4% from 2009 to 2011.
MarketsandMarkets is a research and consulting firm that publishes 120 market reports per year. Each strategically analyzed report contains in-depth, five-level segmentation for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports also analyze about 200 patents, over 40 companies and micro markets that are mutually exclusive and collectively exhaustive. Browse all our 120 titles at www.marketsandmarkets.com.